Restless Legs Syndrome
An overwhelming evening urge to move the legs to relieve uncomfortable sensations, strongly linked to low brain iron and dopaminergic dysfunction, causing severe insomnia.
Emergency Management: Not typically associated with acute medical emergencies, but profound insomnia can lead to severe psychiatric crises or suicidal ideation.
Restless Legs Syndrome (RLS) is a sensorimotor neurological disorder characterized by an irresistible urge to move the legs, usually accompanied by uncomfortable and unpleasant dysesthesias in the lower extremities. The symptoms are exclusively exacerbated by rest or inactivity, predominantly occur in the evening or night, and are transiently relieved by movement.
Detailed Overview
RLS causes significant sleep disruption, leading to severe chronic daytime fatigue and impaired quality of life. The pathophysiology is heavily tied to central nervous system iron deficiency and dopaminergic dysfunction. RLS can be primary (idiopathic, often familial) or secondary to other conditions like end-stage renal disease (ESRD), pregnancy, or severe iron deficiency anemia. Over 80% of RLS patients also exhibit Periodic Limb Movements of Sleep (PLMS), consisting of involuntary leg twitching during non-REM sleep.
Epidemiology & Demographics
Prevalence is approximately 5-10% in North American and European adult populations. It is twice as common in women than in men. Onset can occur at any age, but severity usually increases with advancing age.
Etiological Mechanism
Primary RLS has a strong genetic component (autosomal dominant pattern in familial cases, involving variants in MEIS1 and BTBD9 genes). Secondary RLS is caused by states of systemic iron deficiency, uremia, or pregnancy (particularly the 3rd trimester).
Primary Causes
Central Iron Deficiency
Genetic Predisposition
Pregnancy
End-Stage Renal Disease (Uremia)
The core pathology involves diminished iron stores in the brain, specifically within the substantia nigra and basal ganglia, despite normal peripheral serum iron in primary cases. Iron is a crucial co-factor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. This central iron deficiency leads to abnormal presynaptic dopamine transmission. Consequently, there is impaired descending dopaminergic inhibition of spinal sensorimotor pathways, resulting in hyper-excitability of the spinal cord that manifests as sensory discomfort and motor restlessness during periods of low sensory input (rest/night).
Diagnostic Criteria & Guidelines
Diagnosis is strictly clinical based on the 4 IRLSSG criteria: 1) Urge to move legs usually with dysesthesia; 2) Worsens with rest; 3) Relieved by movement; 4) Worsens in the evening/night. These must not be accounted for by another condition (mimics).
Alpha-2-Delta Calcium Channel Ligands: Gabapentin Enacarbil 600 mg PO daily at 5 PM, or Pregabalin 75-150 mg PO 2 hours before bedtime. Simultaneously, oral iron therapy (Ferrous Sulfate 325 mg PO every other day with Vitamin C) if ferritin is < 75 ng/mL.
Second-Line & Adjunctive Therapy
Dopamine Agonists (Pramipexole 0.125-0.25 mg PO or Ropinirole 0.5-1 mg PO 2 hours prior to sleep). Used cautiously due to high risk of augmentation. For severe refractory cases: low-dose opioids (Methadone 5 mg PO) or IV iron formulations (Ferric carboxymaltose).
Surgical & Procedural Management
Not applicable for RLS.
Patient Counseling & Advice
Warn patients prescribed dopamine agonists about the risk of Impulse Control Disorders (gambling, hypersexuality) and Augmentation. Instruct them to take iron supplements on an empty stomach with orange juice for best absorption.
Follow-Up & Monitoring Schedule
Assess severity using the IRLS rating scale. Monitor serum ferritin every 3 months until > 75 ng/mL. Continually screen for signs of symptom augmentation if on dopaminergic agents.
Preventive Strategies
Maintaining adequate iron stores is the main preventative measure for individuals predisposed to RLS.
RLS is a lifelong condition that tends to progress slowly over decades. It does not lead to neurodegeneration (like Parkinson disease), but severely impacts quality of life if untreated.